GB201520949D0 - Inhibitors - Google Patents
InhibitorsInfo
- Publication number
- GB201520949D0 GB201520949D0 GBGB1520949.7A GB201520949A GB201520949D0 GB 201520949 D0 GB201520949 D0 GB 201520949D0 GB 201520949 A GB201520949 A GB 201520949A GB 201520949 D0 GB201520949 D0 GB 201520949D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G01N33/57515—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520949.7A GB201520949D0 (en) | 2015-11-27 | 2015-11-27 | Inhibitors |
| PCT/GB2016/053729 WO2017089833A1 (en) | 2015-11-27 | 2016-11-28 | Srebp transcription factor as biomarker for aromatase inhibitor resistance in oestrogen receptor a positive cancers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520949.7A GB201520949D0 (en) | 2015-11-27 | 2015-11-27 | Inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201520949D0 true GB201520949D0 (en) | 2016-01-13 |
Family
ID=55177331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1520949.7A Ceased GB201520949D0 (en) | 2015-11-27 | 2015-11-27 | Inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201520949D0 (en) |
| WO (1) | WO2017089833A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020077361A1 (en) * | 2018-10-12 | 2020-04-16 | The General Hospital Corporation | Compounds and methods of their use |
| CA3253436A1 (en) * | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100120039A1 (en) * | 2008-08-27 | 2010-05-13 | Suzanne Fuqua | Methods and compositions in breast cancer therapy resistance |
| WO2012097820A1 (en) * | 2011-01-20 | 2012-07-26 | Syddansk Universitet | Method and assay for predicting long-term efficacy of tamoxifen treatment in estrogen receptor-positive breast cancer patients |
-
2015
- 2015-11-27 GB GBGB1520949.7A patent/GB201520949D0/en not_active Ceased
-
2016
- 2016-11-28 WO PCT/GB2016/053729 patent/WO2017089833A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017089833A1 (en) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | Smyd inhibitors | |
| IL260217B (en) | Lsd1 inhibitors | |
| IL255006A0 (en) | Bromodomain inhibitors | |
| IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| IL251784A0 (en) | Bromodomain inhibitors | |
| SG11201802665VA (en) | Ferroportin inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| IL256427A (en) | Ido inhibitors | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201612860D0 (en) | Inhibitors | |
| GB201505658D0 (en) | Inhibitor compounds | |
| IL253471A0 (en) | Autotaxin inhibitors | |
| ZA201800638B (en) | Fucosidase inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| AU361999S (en) | Ballustrade | |
| DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
| IL253322A0 (en) | Bace1 inhibitors | |
| DK3242882T3 (en) | Cgrp-antagonistpeptider | |
| GB201520949D0 (en) | Inhibitors | |
| DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
| GB201401005D0 (en) | Inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |